Indication

For the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Medicine details

Medicine name:
brentuximab (Adcetris)
SMC ID:
SMC2229
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q1 2020
SMC meeting date:
Q1 2020
Patient group submission deadline:
04 November 2019